Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Int. j. cardiovasc. sci. (Impr.) ; 34(2): 116-121, Mar.-Apr. 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1154561

RESUMO

Abstract Background Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT / INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. Int J Cardiovasc Sci. 2020; [online].ahead print, PP.0-0


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Fibrilação Atrial/tratamento farmacológico , Rivaroxabana/farmacologia , Tempo de Protrombina , Fibrilação Atrial/prevenção & controle , Varfarina/farmacologia , Medição de Risco , Coeficiente Internacional Normatizado
2.
Rev. méd. Minas Gerais ; 24(2)jun. 2014.
Artigo em Português | LILACS-Express | LILACS | ID: lil-725978

RESUMO

A miocardite constitui-se em um dos diagnósticos mais desafiadores em Cardiologia, pois raramente é reconhecida clinicamente. Além disso, não existe um exame que seja padrão-ouro para o diagnóstico e o tratamento atual permanece controverso. O objetivo deste relato de caso é descrever a importância do diagnóstico precoce de miocardite aguda fulminante, na avaliação de paciente com dor torácica e história clínica sugestiva que, após tratamento adequado, apresentou evolução favorável.


The myocarditis constitutes one of the most challenging diagnoses in cardiology because it is rarely recognized clinically. In addition, there is no gold standard exam for the diagnosis and current treatment remains controversial. The objective of this case report is to describe the importance of early diagnosis of acute fulminant myocarditis in the evaluation of patients with chest pain and clinical history that is suggestive that after appropriate treatment, presented favorable evolution.

3.
RELAMPA, Rev. Lat.-Am. Marcapasso Arritm ; 26(2): 116-118, abr.-jun .2013.
Artigo em Português | LILACS | ID: lil-711870

RESUMO

A endomiocardiofibrose é uma causa importante de cardiopatia restritiva na zona tropical, ocasionalmente verificada no Brasil. Caracteriza-se pelo espessamento fibroso do endocárdio e do miocárdio subjacente, com progressão tardia para insuficiência cardíaca grave e prognóstico reservado. Relata-se aqui uma apresentação infrequente da doença: a insuficiência cardíaca de baixo débito, secundária a bloqueio atrioventricular avançado. O paciente foi tratado com sucesso por meio de implante de marcapasso DDD/R e encontra-se em classe funcional I (NYHA) há dois anos.


Endomyocardial fibrosis is an important cause of restrictive cardiomyopathy observed in tropical areas and has been occasionally found in Brazil. It is characterized by fibrous thickening of the endocardium and underlying myocardium with late progression to severe heart failure and poor prognosis. We report an unusual presentation of the disease: low output heart failure secondary to advanced atrioventricular block. The patient was successfully treated by implanting a DDD/R pacemaker and has been in functional class I (NYHA) for 2 years.


Assuntos
Humanos , Bloqueio Atrioventricular , Fibrose Endomiocárdica/diagnóstico , Insuficiência Cardíaca/prevenção & controle , Ecocardiografia , Eletrocardiografia Ambulatorial , Marca-Passo Artificial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA